Kidney cancer combo trial halted early – what we know
NCT ID NCT05935748
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tested a new drug (NKT2152) combined with two other medicines (palbociclib and sasanlimab) in people with advanced clear cell kidney cancer that had worsened after prior treatments. The goal was to see if the combination was safe and could shrink tumors. The trial was stopped early after enrolling only 18 participants, so results are limited.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Phase 2
Tests whether the treatment actually works, and watches for side effects, in a larger group.
- Participants
-
18 people
The number who actually took part.
- Started
-
Jul 2023
- Finished
-
Sep 2025
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
18 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Must have locally advanced or metastatic ccRCC and have progressed or relapsed after at least 1 prior anti-VEGF/VEGFR systemic therapy and 1 ICI. * Measurable disease per the Response Evaluation Criteria in Solid Tumors version 1.1 (RECIST 1.1) * KPS score of at least 70% * Able to swallow oral medications. Exclusion Criteria: * Active CNS metastases and/or carcinomatous meningitis * Has had any major cardiovascular event within 6 months or clinically significant cardiovascular disease * Major surgery (eg, GI surgery, removal or biopsy of brain metastasis) within 3 months before administration of study drug. * Has known HIV * History of hepatitis B or known active hepatitis C infection * Has received prior treatment with NKT2152, other HIF2α inhibitors, other CDK 4/6 inhibitors, palbociclib, or sasanlimab * Radiation therapy for bone metastasis within 2 weeks, or any other external radiation therapy within 4 weeks before administration of the first dose of study treatment * Corrected QT interval calculated by Fridericia formula (QTcF) \> 480 ms within 28 days prior to first dose * Hypoxia or requires intermittent or chronic supplemental oxygen or any chronic lung condition which has required supplemental oxygen in the past * Has a history of interstitial lung disease * Has any active or recent history of a known or suspected autoimmune disease
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Adenocarcinoma are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States
-
Memorial Sloan Kettering Cancer Center
New York, New York, 10065-6094, United States
-
Nebraska Cancer Specialists
Omaha, Nebraska, 68130, United States
-
Northwestern University - Feinberg School of Medicine
Chicago, Illinois, 60611, United States
-
UT Southwestern Medical Center
Dallas, Texas, 75390-9324, United States
-
University of California San Diego
La Jolla, California, 92093, United States
-
University of Michigan-Rogel Cancer Center
Ann Arbor, Michigan, 48109, United States
-
University of Virginia Health System
Charlottesville, Virginia, 22908, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a PET scan reveal who will respond to kidney cancer therapy?
- A pill instead of surgery? trial tests vepugratinib against Low-Grade bladder cancer
- New antibody GNR-051 tested for safety in Hard-to-Treat cancers
- When cancer blocks the airway, doctors lack a playbook. experts aim to write one.
- Robotic surgery vs standard approaches: does the platform change cancer outcomes?
- New antibody aims to preserve immune checkpoint while fighting cancer